Allergan marks opening of new €160m biologics facility in Westport with 63 new jobs
29 January, 2020
Allergan plc, the global integrated biopharmaceutical leader headquartered in Ireland, yesterday marked the opening of its €160m state-of-the-art Biologics 2 facility at its Westport Campus in Co. Mayo, Ireland. The new facility will create 63 jobs and enhance Ireland’s position as a strategic global hub for Allergans’ flagship products, including their botulinum toxin brand. This brings Allergan’s total investment in Ireland since it began operations in the country to more than €750m.
The Biologics 2 facility at Allergan Westport will feature new manufacturing suites to meet growing global demand for Allergan’s flagship products. As part of a strategic expansion to support the next generation of biologics innovation it will feature a new state-of-the-art microbiology and cell-based laboratory with world-class technology and research and development capabilities to support advances in discovery, development and manufacturing.
Coinciding with the opening of the Biologics 2 facility, Allergan recently marked the shipping of the 100 millionth vial of BOTOX® from the Westport campus as Allergan marked 30 years since the product first received FDA approval.
Employing over to 2,000 across the country, one in ten employees in Allergan’s global workforce are now based in Ireland.
An independent economic assessment by EY DKM conducted in 2019 indicates that Allergans’ €160m capital investment programme in Ireland over the past 3 years contributed €23 million to Ireland’s GDP in 2019 and added €7 million in exchequer revenues. In 2018, Allergan’s significant Irish operations delivered a GDP impact of €308 million, supported 3,485 jobs in Ireland’s economy, and contributed exchequer revenues of €76 million.
For more information click HERE.